Skip to main content
Onconic Therapeutics Inc. logo

Onconic Therapeutics Inc. — Investor Relations & Filings

Ticker · 476060 ISIN · KR7476060009 KO Manufacturing
Open in API
Filings indexed 125 across all filing types
Latest filing 2026-03-09 Regulatory Filings
Country KR South Korea
Listing KO 476060

About Onconic Therapeutics Inc.

http://onconic.co.kr/

Onconic Therapeutics Inc., established in 2020, is a biopharmaceutical company specializing in the research and development of innovative drugs. A subsidiary of Jeil Pharmaceutical, the company focuses on creating novel treatments for cancer and gastrointestinal disorders, including gastroesophageal reflux disease. Its development strategy prioritizes therapeutics for conditions with high unmet medical needs and significant market potential. Onconic Therapeutics actively advances its pipeline of drug candidates through various stages of clinical trials.

Recent filings

Filing Released Lang Actions
투자판단관련주요경영사항(임상시험계획변경승인) (네수파립(JPI547)의 음식물 영향 및 인종 간 차이 확인을 위한 제1상 임상시험계획승인(변경승인))
Regulatory Filings Classification · 95% confidence The document is a regulatory filing from a Korean company (Onconic Therapeutics) regarding the approval of a clinical trial plan (IND amendment). It follows the standard format for 'Major Management Matters' (투자판단 관련 주요경영사항) as required by the Korea Exchange (KRX). Since it does not fit into specific categories like financial reports, dividends, or M&A, and serves as a formal regulatory disclosure of clinical trial status, it is classified as a Regulatory Filing (RNS).
2026-03-09 Korean
주주총회소집결의
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a formal 'Notice of General Meeting of Shareholders' (주주총회소집결의) issued by Onconic Therapeutics. It details the date, location, and specific agenda items for the upcoming Annual General Meeting (AGM), including the approval of financial statements, election of directors, and remuneration limits. This document serves as the official proxy solicitation and information statement provided to shareholders to inform them of the meeting and request their votes on the listed agenda items.
2026-03-06 Korean
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a 'Notice of General Meeting of Shareholders' (주주총회소집공고) for Onconic Therapeutics. It contains the agenda for the upcoming Annual General Meeting (AGM), including items such as the approval of financial statements, election of directors, and remuneration limits. While it contains financial data, it is primarily a proxy solicitation document sent to shareholders to inform them of the meeting and request their votes. According to the filing definitions, documents requesting votes for meetings are classified as Proxy Solicitation & Information Statement (PSI).
2026-03-06 Korean
의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled '의결권대리행사권유참고서류' (Proxy Solicitation Reference Document) and contains detailed information regarding an upcoming Annual General Meeting (AGM), including the purpose of the meeting, voting procedures, financial statements, and proposed amendments to the Articles of Incorporation. This document is a formal solicitation of proxies from shareholders to ensure a quorum and facilitate voting at the meeting, which fits the definition of a Proxy Solicitation & Information Statement.
2026-03-06 Korean
[기재정정]매출액또는손익구조30%(대규모법인은15%)이상변동
Regulatory Filings Classification · 95% confidence The document is a regulatory filing from the Korea Exchange (KRX) system regarding a 'Change in Sales or Profit/Loss Structure' (30% or more). It includes a correction notice ('정정신고') for a previous filing. This type of disclosure is a standard regulatory requirement for listed companies to report significant financial changes. It is not a full annual report (10-K) or an earnings release (ER) in the traditional sense, but rather a specific regulatory disclosure form. Given the options, 'RNS' (Regulatory Filings) is the most appropriate fallback category for this type of mandatory exchange disclosure.
2026-03-06 Korean
[기재정정]매출액또는손익구조30%(대규모법인은15%)이상변동
Regulatory Filings Classification · 95% confidence The document is a regulatory filing from a Korean company (Onconic Therapeutics) regarding a correction to a previously filed 'Change in Sales or Profit/Loss Structure' report. This type of filing is a standard regulatory disclosure required by the Korea Exchange (KRX) when financial figures change due to audit results. Since it is a specific regulatory disclosure of financial performance changes rather than a full annual report or a simple announcement of a report's publication, it falls under the 'Regulatory Filings' category.
2026-03-06 Korean

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.